Trials / Completed
CompletedNCT00594464
A Trial of Neupro® (Rotigotine Transdermal Patch) in Patients With Parkinson's Disease Undergoing Surgery
An Explorative, Multicenter, Open-label Pilot Trial With Neupro® (Rotigotine Transdermal Patch) Once Daily Treatment Administered Perioperatively in Patients With Idiopathic Parkinson's Disease
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of efficacy and safety on the use of rotigotine in patients suffering from Parkinson's Disease during and after surgery requiring general anaesthesia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rotigotine | 2 mg/24 h, 4 mg/24 h, 6 mg/24 h and 8 mg/24 h patch; Single patches and a combination of 2 of these patches for a dosage of up to 16 mg/24 h; One (1) regimen on day of surgery, but exceptionally extended for up to 2 (two) weeks if the patient requires unexpected ventilation after surgery. |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2008-05-01
- Completion
- 2008-05-01
- First posted
- 2008-01-15
- Last updated
- 2014-10-02
- Results posted
- 2009-07-03
Locations
12 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT00594464. Inclusion in this directory is not an endorsement.